Innovator’s Pitch Challenge

Vote for Us

Interested in Connecting? Please contact:
Randy Berholtz
CEO
rberholtz@rsfbio.com

Message the company or request a 1:1 meeting here

Rancho Santa Fe Bio, Inc., is a clinical stage, calcific disorders company based in San Diego.  Our first drug, Ataciguat, has been exclusively licensed from Sanofi and Mayo Clinic and is entering into Phase III clinical trials in the US, the EU, the UK and Canada for the treatment of moderate calcific aortic valve stenosis (“CAVS”).  We are also (a) researching additional indications for our drug in the following areas:  post-TAVR use in CAVS and peripheral artery disease (“PAD”) among others and (b) reviewing ten new in-licensed small molecules for potential next generation drugs in the CAVS and other calcific disorders fields.  The company is raising a Series A financing to fund its Phase III clinical trial.

Pitch Video

Slide Deck